Logo image of SNCE

SCIENCE 37 HOLDINGS INC (SNCE) Stock Fundamental Analysis

NASDAQ:SNCE - Nasdaq - US8086442071 - Common Stock - Currency: USD

5.75  +0.02 (+0.35%)

After market: 5.7203 -0.03 (-0.52%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SNCE. SNCE was compared to 57 industry peers in the Life Sciences Tools & Services industry. SNCE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SNCE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SNCE has reported negative net income.
In the past year SNCE has reported a negative cash flow from operations.
SNCE Yearly Net Income VS EBIT VS OCF VS FCFSNCE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

SNCE's Return On Assets of -164.66% is on the low side compared to the rest of the industry. SNCE is outperformed by 98.31% of its industry peers.
The Return On Equity of SNCE (-241.10%) is worse than 88.14% of its industry peers.
Industry RankSector Rank
ROA -164.66%
ROE -241.1%
ROIC N/A
ROA(3y)-44.02%
ROA(5y)N/A
ROE(3y)-71.84%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SNCE Yearly ROA, ROE, ROICSNCE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 -20 -40 -60 -80

1.3 Margins

SNCE has a worse Gross Margin (29.75%) than 72.88% of its industry peers.
The Profit Margin and Operating Margin are not available for SNCE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNCE Yearly Profit, Operating, Gross MarginsSNCE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 0 -50 -100 -150

More info and screens

6

2. Health

2.1 Basic Checks

SNCE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SNCE has more shares outstanding
SNCE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SNCE Yearly Shares OutstandingSNCE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 20M 40M 60M 80M 100M
SNCE Yearly Total Debt VS Total AssetsSNCE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

SNCE has an Altman-Z score of -5.81. This is a bad value and indicates that SNCE is not financially healthy and even has some risk of bankruptcy.
SNCE's Altman-Z score of -5.81 is on the low side compared to the rest of the industry. SNCE is outperformed by 93.22% of its industry peers.
There is no outstanding debt for SNCE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.81
ROIC/WACCN/A
WACC11.9%
SNCE Yearly LT Debt VS Equity VS FCFSNCE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 50M -50M 100M -100M

2.3 Liquidity

SNCE has a Current Ratio of 4.17. This indicates that SNCE is financially healthy and has no problem in meeting its short term obligations.
SNCE has a Current ratio of 4.17. This is in the better half of the industry: SNCE outperforms 62.71% of its industry peers.
A Quick Ratio of 4.17 indicates that SNCE has no problem at all paying its short term obligations.
With a decent Quick ratio value of 4.17, SNCE is doing good in the industry, outperforming 67.80% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.17
Quick Ratio 4.17
SNCE Yearly Current Assets VS Current LiabilitesSNCE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for SNCE have decreased strongly by -881.08% in the last year.
Looking at the last year, SNCE shows a very negative growth in Revenue. The Revenue has decreased by -19.21% in the last year.
EPS 1Y (TTM)-881.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-429.41%
Revenue 1Y (TTM)-19.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-8.37%

3.2 Future

SNCE is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.15% yearly.
The Revenue is expected to grow by 14.73% on average over the next years. This is quite good.
EPS Next Y-72.66%
EPS Next 2Y-1.9%
EPS Next 3Y-0.15%
EPS Next 5YN/A
Revenue Next Year-14.69%
Revenue Next 2Y-4.18%
Revenue Next 3Y3.19%
Revenue Next 5Y14.73%

3.3 Evolution

SNCE Yearly Revenue VS EstimatesSNCE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
SNCE Yearly EPS VS EstimatesSNCE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNCE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNCE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNCE Price Earnings VS Forward Price EarningsSNCE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNCE Per share dataSNCE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.9%
EPS Next 3Y-0.15%

More info and screens

0

5. Dividend

5.1 Amount

SNCE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCIENCE 37 HOLDINGS INC

NASDAQ:SNCE (3/11/2024, 6:05:35 PM)

After market: 5.7203 -0.03 (-0.52%)

5.75

+0.02 (+0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-04 2024-03-04/amc
Earnings (Next)05-13 2024-05-13/bmo
Inst Owners0.02%
Inst Owner Change0%
Ins Owners287.18%
Ins Owner Change0%
Market Cap34.67M
Analysts76
Price Target14.11 (145.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.04%
Min EPS beat(2)36.97%
Max EPS beat(2)45.1%
EPS beat(4)4
Avg EPS beat(4)31.49%
Min EPS beat(4)21.57%
Max EPS beat(4)45.1%
EPS beat(8)7
Avg EPS beat(8)20.64%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)9.12%
Min Revenue beat(2)-1.56%
Max Revenue beat(2)19.79%
Revenue beat(4)3
Avg Revenue beat(4)8.87%
Min Revenue beat(4)-1.56%
Max Revenue beat(4)19.79%
Revenue beat(8)5
Avg Revenue beat(8)8.69%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-51.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1950%
EPS NY rev (1m)0%
EPS NY rev (3m)-1907.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.58
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)-7.26
EYN/A
EPS(NY)-3.45
Fwd EYN/A
FCF(TTM)-12.22
FCFYN/A
OCF(TTM)-7.99
OCFYN/A
SpS10
BVpS8.57
TBVpS8.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -164.66%
ROE -241.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.75%
FCFM N/A
ROA(3y)-44.02%
ROA(5y)N/A
ROE(3y)-71.84%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 432.94%
Cap/Sales 42.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.17
Quick Ratio 4.17
Altman-Z -5.81
F-Score5
WACC11.9%
ROIC/WACCN/A
Cap/Depr(3y)193.38%
Cap/Depr(5y)N/A
Cap/Sales(3y)35.33%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-881.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-429.41%
EPS Next Y-72.66%
EPS Next 2Y-1.9%
EPS Next 3Y-0.15%
EPS Next 5YN/A
Revenue 1Y (TTM)-19.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-8.37%
Revenue Next Year-14.69%
Revenue Next 2Y-4.18%
Revenue Next 3Y3.19%
Revenue Next 5Y14.73%
EBIT growth 1Y48.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.54%
EBIT Next 3Y25.26%
EBIT Next 5Y19.21%
FCF growth 1Y-173.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-224.62%
OCF growth 3YN/A
OCF growth 5YN/A